CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 2,091 enrolled
Drug / intervention
Symbicort Turbuhaler +1 moredrug
Likely dose
Symbicort Turbuhaler 4.5 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00839800
NCT00839800Phase 3Completed
CompareCT.gov

A Comparison of Symbicort® SMART (160/4.5μg) and Symbicort® Turbuhaler 160/4.5 μg, Plus Terbutaline Turbuhaler 0.4 mg as Needed, for Treatment of Asthma - a 12-month, Randomized, Double-blind, Parallel Group, Active-controlled, Multinational Phase III Study in Asthmatic Patients From 16 Years

AstraZeneca·interventional·Posted Feb 10, 2009·Updated Nov 30, 2012

In Brief

A Phase 3 clinical trial evaluating Symbicort Turbuhaler and Terbutaline Turbuhaler for Asthma. Completed, enrolled 2,091 participants across 109 sites in 12 countries.

Detailed Summary

The primary objective of this study is to compare the efficacy of Symbicort SMART (Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus as needed) with Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus terbutaline Turbuhaler 0.4 mg as needed, as asthma therapy

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesArgentina, Brazil, China, Costa Rica, Hungary, India, Japan, Malaysia, Peru, Philippines, South Korea, Thailand
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 10, 2009
Enrollment StartFeb 1, 2009
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 17.4 years ago

Interventions

Symbicort Turbuhalerdrug

160/4.5 µg

Terbutaline Turbuhalerdrug

0.4 mg